Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT›References

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 16 min read

  1. Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, et al.; BEEP study team. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet 2020;395:962–72.32087126
  2. Flohr C, Johansson SG, Wahlgren CF, Williams H. How atopic is atopic dermatitis? J Allergy Clin Immunol 2004;114:150–8.15241359
  3. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832–6.15131563
  4. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994;131:406–16.7918017
  5. Williams H. UK Diagnostic Criteria for Atopic Dermatitis – Training Manual. URL: https://nottingham.ac.uk/research/groups/cebd/resources/uk-diagnostic-criteria-for-atopic-dermatitis.aspx (accessed 1 September 2022).
  6. Simpson EL, Keck LE, Chalmers JR, Williams HC. How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies. J Allergy Clin Immunol 2012;130:137–44.22424882
  7. Endre KMA, Landrø L, LeBlanc M, Gjersvik P, Lødrup Carlsen KC, Haugen G, et al. Diagnosing atopic dermatitis in infancy using established diagnostic criteria: a cohort study. Br J Dermatol 2022;186:50–8.33511639
  8. Williams HC. Atopic eczema – we should look to the environment. BMJ 1995;311:1241.7496218
  9. Williams HC, Strachan DP, Hay RJ. Childhood eczema: disease of the advantaged? BMJ 1994;308:1132–5.8173454
  10. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR; International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups. Is eczema really on the increase worldwide? J Allergy Clin Immunol 2008;121:947–54.e15.18155278
  11. Petersen EBM, Skov L, Thyssen JP, Jensen P. Role of the gut microbiota in atopic dermatitis: a systematic review. Acta Derm Venereol 2019;99:5–11.30085318
  12. Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. J Am Acad Dermatol 2016;75:681–87.e11.27544489
  13. Bosma AL, Ascott A, Iskandar R, Farquhar K, Matthewman J, Langendam MW, et al. Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics. J Eur Acad Dermatol Venereol 2022;36:807–19.35170821
  14. Cork MJ, Danby SG, Ogg GS. Atopic dermatitis epidemiology and unmet need in the United Kingdom. J Dermatolog Treat 2020;31:801–9.31631717
  15. Davidson WF, Leung DYM, Beck LA, Berin CM, Boguniewicz M, Busse WW, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on ‘atopic dermatitis and the atopic march: mechanisms and interventions’. J Allergy Clin Immunol 2019;143:894–913.30639346
  16. Yaneva M, Darlenski R. The link between atopic dermatitis and asthma-immunological imbalance and beyond. Asthma Res Pract 2021;7:16.34911576
  17. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI; ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009;124:1251–8.e23.20004783
  18. Kan T, Tanaka A, Kanamoto M, Morioke S, Takahagi S, Hide M. Longitudinal prevalence of atopic dermatitis among freshmen at Hiroshima University between 2002 and 2019. J Dermatol 2022;49:724–8.35315120
  19. Williams HC, Pembroke AC, Forsdyke H, Boodoo G, Hay RJ, Burney PG. London-born black Caribbean children are at increased risk of atopic dermatitis. J Am Acad Dermatol 1995;32:212–7.7829705
  20. Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis 2014;25:107–14.24819283
  21. Blome C, Radtke MA, Eissing L, Augustin M. Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am J Clin Dermatol 2016;17:163–9.26818063
  22. Hebert AA, Stingl G, Ho LK, Lynde C, Cappelleri JC, Tallman AM, et al. Patient impact and economic burden of mild-to-moderate atopic dermatitis. Curr Med Res Opin 2018;34:2177–85.29985061
  23. National Institute for Health and Care Excellence (NICE) Eczema Clinical Knowledge Summary. URL: https://cks.nice.org.uk/topics/eczema-atopic/ (accessed 1 August 2022).
  24. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol 2004;140:1513–9.15611432
  25. Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013;169:1326–32.24024631
  26. Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatology 2022;158:523–32.35293977
  27. Wise J. NICE recommends three more treatments for atopic dermatitis. BMJ 2022;377:o1618.35772780
  28. EczemaCareOnline. Eczema Care Online Tool Kit. URL: https://eczemacareonline.org.uk/en?language_set=1 (accessed 31 July 2022).
  29. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020;396:345–60.32738956
  30. Williams HC. Epidemiology of Atopic Dermatitis. In Harper J, Oranje A, Prose N, editors. Textbook of Pediatric Dermatology. Oxford: Blackwell Scientific; 2000. pp. 161–8.
  31. Williams H. Epidemiology of Skin Disease. In Rook’s Textbook of Dermatology. 9th edn. Oxford, Wiley Blackwell; 2016.
  32. Williams HC, Chalmers J. Prevention of atopic dermatitis. Acta Derm Venereol 2020;100:adv00166.32419030
  33. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441–6.16550169
  34. Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol 2012;132:751–62.22158554
  35. Kim BE, Leung DYM. Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res 2018;10:207–15.29676067
  36. Tang TS, Bieber T, Williams HC. Does ‘autoreactivity’ play a role in atopic dermatitis? J Allergy Clin Immunol 2012;129:1209–1215.e2.22409986
  37. Madan I, Parsons V, Ntani G, Coggon D, Wright A, English J, et al. A behaviour change package to prevent hand dermatitis in nurses working in the National Health Service: results of a cluster randomized controlled trial. Br J Dermatol 2020;183:462–70.31989580
  38. Edwards WH, Conner JM, Soll RF; Vermont Oxford Network Neonatal Skin Care Study Group. The effect of prophylactic ointment therapy on nosocomial sepsis rates and skin integrity in infants with birth weights of 501 to 1000 g. Pediatrics 2004;113:1195–203.15121929
  39. van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. Cochrane Database Syst Rev 2017;2:CD012119.
  40. Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol 2010;63:587–93.20692725
  41. Macharia WM, Anabwani GM, Owili DM. Effects of skin contactants on evolution of atopic dermatitis in children: a case control study. Trop Doct 1991;21:104–6.1926547
  42. Thomas KS, Batchelor JM, Bath-Hextall F, Chalmers JR, Clarke T, Crowe S, et al. Programme Grants for Applied Research. In A Programme of Research to Set Priorities and Reduce Uncertainties for the Prevention and Treatment of Skin Disease. Southampton (UK): NIHR Journals Library; 2016.
  43. Cork MJ, Danby S. Aqueous cream damages the skin barrier. Br J Dermatol 2011;164:1179–80.21615367
  44. Danby SG, Chalmers J, Brown K, Williams HC, Cork MJ. A functional mechanistic study of the effect of emollients on the structure and function of the skin barrier. Br J Dermatol 2016;175:1011–9.27097823
  45. Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol 2014;134:824–30.e6.25282564
  46. Chalmers JR, Haines RH, Mitchell EJ, Thomas KS, Brown SJ, Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial. Trials 2017;18:343.28732519
  47. NIHR Funding and Awards. A Randomised Controlled Trial to Determine Whether Skin Barrier Enhancement With Emollients Can Prevent Eczema in High Risk Children (12/67/12). URL: https://fundingawards.nihr.ac.uk/award/12/67/12 (accessed 1 September 2022).
  48. SWAT 25. Two-by-two Factorial Randomised Trial to Evaluate Strategies to Improve Follow-up in a Randomised Prevention Trial. URL: https://qub.ac.uk/sites/TheNorthernIrelandNetworkforTrialsMethodologyResearch/FileStore/Filetoupload,976688,en.pdf (accessed 5 September 2022).
  49. Barbier N, Paul C, Luger T, Allen R, De Prost Y, Papp K, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004;150:96–102.14746622
  50. Stevens K. Valuation of the Child Health Utility 9D Index. PharmacoEconomics 2012;30:729–47.22788262
  51. Khan KA, Petrou S, Rivero-Arias O, Walters SJ, Boyle SE. Mapping EQ-5D utility scores from the PedsQL™ generic core scales. PharmacoEconomics 2014;32:693–706.24715604
  52. Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants’ Dermatitis Quality of Life Index. Br J Dermatol 2001;144:104–10.11167690
  53. Postnatal Care NICE guideline [NG194] . URL: www.nice.org.uk/guidance/ng194 (accessed 3 January 2024).
  54. Holme N, Boullier L, Harrison C. Postnatal care: a neonatal perspective (NICE guideline CG 37 ). Arch Dis Child Educ Pract Ed. 2016;101:136–8.
  55. BSACI Standard Operating Procedure: Paediatric Allergy Skin Prick Testing. URL: https://bsaci.org/wp-content/uploads/2019/12/paedSPTnew.pdf (accessed 5 September 2022).
  56. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol 2015;172:1353–7.25580670
  57. Sampson HA, van Wijk RG, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, et al. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma and Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol 2012;130:1260–74.23195525
  58. Grabenhenrich LB, Reich A, Bellach J, Trendelenburg V, Sprikkelman AB, Roberts G, et al. A new framework for the documentation and interpretation of oral food challenges in population-based and clinical research. Allergy 2017;72:453–61.27670637
  59. Kelleher MM, Jay N, Perkin MR, Haines RH, Batt R, Bradshaw LE, et al. An algorithm for diagnosing IgE-mediated food allergy in study participants who do not undergo food challenge. Clin Exp Allergy 2020;50:334–42.31999862
  60. Paternoster L, Savenije OEM, Heron J, Evans DM, Vonk JM, Brunekreef B, et al. Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts. J Allergy Clin Immunol 2018;141:964–71.29129583
  61. The BEEP Study, Participant Newsletter – Results Edition; 2019. URL: https://nottingham.ac.uk/research/groups/cebd/documents/researchdocs/beep-parentsresultsnewsletterweb.pdf (accessed 17 May 2022).
  62. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377–99.21225900
  63. Shrier I, Steele RJ, Verhagen E, Herbert R, Riddell CA, Kaufman JS. Beyond intention to treat: what is the right question? Clin Trials 2014;11:28–37.24096636
  64. Dunn G, Maracy M, Tomenson B. Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods. Stat Methods Med Res 2005;14:369–95.16178138
  65. Carpenter JR, Kenward MG. Missing Data in Randomised Controlled Trials: A Practical Guide. Health Technology Assessment Methodology Programme. Birmingham; 2007. p. 199. https://researchonline.lshtm.ac.uk/id/eprint/4018500 (accessed 5 September 2022).
  66. Norton EC, Miller MM, Kleinman LC. Computing adjusted risk ratios and risk differences in Stata. Stata J 2013;13:492–509.
  67. Cro S, Morris TP, Kenward MG, Carpenter JR. Sensitivity analysis for clinical trials with missing continuous outcome data using controlled multiple imputation: a practical guide. Stat Med 2020;39:2815–42.32419182
  68. Raftery J, Williams H, Clarke A, Thornton J, Norrie J, Snooks H, Stein K. ‘Not clinically effective but cost-effective’ – paradoxical conclusions in randomised controlled trials with ‘doubly null’ results: a cross-sectional study. BMJ Open 2020;10:e029596.
  69. Xu S, Immaneni S, Hazen GB, Silverberg JI, Paller AS, Lio PA. Cost-effectiveness of prophylactic moisturization for atopic dermatitis. JAMA Pediatrics 2017;171:e163909–09-e.27918774
  70. Sach TH, McManus E, Levell NJ. Economic evidence for the prevention and treatment of atopic eczema. Br J Dermatol 2019;181:e95-e.
  71. McManus E, Sach T, Levell N. The use of decision-analytic models in atopic eczema: a systematic review and critical appraisal. PharmacoEconomics 2018;36:51–66.28864846
  72. Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 2005;115:e600–14.15867026
  73. Petrou S. Methodological issues raised by preference-based approaches to measuring the health status of children. Health Econ 2003;12:697–702.12898666
  74. Petrou S, Gray R. Methodological challenges posed by economic evaluations of early childhood intervention programmes. Appl Health Econ Health Policy 2005;4:175–81.16309335
  75. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR good research practices task force report. Value Health 2015;18:161–72.25773551
  76. Glick H, Doshi J, Sonnad S, Polsky D. Economic Evaluation in Clinical Trials. Handbooks in Health Economic Evaluation. 2nd edn. Oxford: Oxford University Press; 2014.
  77. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health 2022;25:10–31.35031088
  78. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. 2013. URL: www.nice.org.uk/process/pmg9/chapter/the-reference-case (accessed 26 July 2018).
  79. Drummond M, Sculpher M, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th edn. Oxford: Oxford University Press; 2015.
  80. NICE Health Technology Evaluations: The Manual. 2022. URL: www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation (accessed 5 September 2022).
  81. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708–15.22867780
  82. Hernandez Alava M, Pudney S, Wailoo A. The EQ-5D-5L value set for England: findings of a quality assurance program. Value Health 2020;23:642–8.32389230
  83. Hernandez Alava M, Wailoo A, Pudney S. Methods for Mapping Between the EQ 5D 5L and the 3L. NICE Decision Support Unit report; 2017. URL: https://sheffield.ac.uk/nice-dsu/methods-development/mapping-eq-5d-5l-3l (accessed 5 September 2022).
  84. NHS Business Services Authority. Prescription Cost Analysis. 2019–20. URL: https://opendata.nhsbsa.net/dataset/prescription-cost-analysis-pca-annual-statistics (accessed 19 July 2022).
  85. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487–96.15497198
  86. Scope A, Bhadhuri A, Pennington B. Systematic review of cost-utility analyses that have included carer and family member health-related quality of life. Value Health 2022;25:1644–53. 10.1016/j.jval.2022.02.00835339379
  87. Gallacher D. HEABS: Stata Module to Calculate the ICER and Net Benefit for up to Two Datasets. URL: https://EconPapers.repec.org/RePEc:boc:bocode:s458438 (accesed 2 September 2022).
  88. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ 2004;13:461–75.15127426
  89. NHS England. NHS Schedule of Reference Costs: 2019–20. 2021. URL: https://england.nhs.uk/publication/2019-20-national-cost-collection-data-publication/ (accessed 1 September 2022).
  90. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEconomics 2014;32:1157–70.25069632
  91. Curtis L, Burns A. Personal Social Services Research Unit, in Unit Costs of Health and Social Care. Canterbury: Personal Social Services Research Unit, University of Kent; 2020.
  92. Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014;134:818–23.25282563
  93. Canaway AG, Frew EJ. Measuring preference-based quality of life in children aged 6–7 years: a comparison of the performance of the CHU-9D and EQ-5D-Y – the WAVES pilot study. Qual Life Res 2013;22:173–83.22302618
  94. Sheffield Clinical Trials Research Unit, Study Protocol, The MAGIC trial (Melatonin for Anxiety prior to General anaesthesia In Children): A Multicentre, Parallel Randomised Controlled Trial of Melatonin Versus Midazolam in the Premedication of Anxious Children Attending for Elective Surgery Under General Anaesthesia, National Institute for Health Research, Version 4.1, September 2020. URL: https://www.sheffield.ac.uk/scharr/research/centres/ctru/magic (accessed 25 July 2022).
  95. Bray N, Noyes J, Harris N, Edwards RT. Measuring the health-related quality of life of children with impaired mobility: examining correlation and agreement between children and parent proxies. BMC Res Notes 2017;10:377.28797288
  96. Kalliomäki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol 2007;119:1019–21.17289135
  97. Papapostolou N, Xepapadaki P, Gregoriou S, Makris M. Atopic dermatitis and food allergy: a complex interplay what we know and what we would like to learn. J Clin Med 2022;11:4232.35887996
  98. Tsakok T, Marrs T, Mohsin M, Baron S, du Toit G, Till S, Flohr C. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol 2016;137:1071–8.26897122
  99. Perkin MR, Logan K, Marrs T, Radulovic S, Craven J, Boyle RJ, et al.; EAT Study Team. Association of frequent moisturizer use in early infancy with the development of food allergy. J Allergy Clin Immunol 2021;147:967–76.e1.33678253
  100. Walker MT, Green JE, Ferrie RP, Queener AM, Kaplan MH, Cook-Mills JM. Mechanism for initiation of food allergy: dependence on skin barrier mutations and environmental allergen costimulation. J Allergy Clin Immunol 2018;141:1711–25.e9.29454836
  101. Flohr, C (2023). TRANS-FOODS: Reducing the risk of developing peanut allergy through the skin by improved understanding, modifying peanut snack production, and adjusting skincare practices. ISRCTN. URL: www.isrctn.com/ISRCTN12492694 (accessed 25 September 2023).
  102. Office for National Statistics. Population Estimates by Ethnic Group and Religion, England and Wales. 2019. URL: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/articles/populationestimatesbyethnicgroupandreligionenglandandwales/2019 (accessed 5 September 2022).
  103. Finlay AY, Griffiths TW, Belmo S, Chowdhury MMU. Why we should abandon the misused descriptor ‘erythema’. Br J Dermatol 2021;185:1240–1.34319584
  104. Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index – a practical guide. Dermatitis 2022;33:187–92.35594457
  105. Centre of Evidence Based Dermatology, University of Nottingham, Test of Your Ability to Diagnose Visible Flexural Dermatitis. URL: https://nottingham.ac.uk/~mzzfaq/dermatology/eczema/TestFotos.html (accessed 8 Jan 2023.
  106. Thawer-Esmail F, Jakasa I, Todd G, Wen Y, Brown SJ, Kroboth K, et al. South African amaXhosa patients with atopic dermatitis have decreased levels of filaggrin breakdown products but no loss-of-function mutations in filaggrin. J Allergy Clin Immunol 2014;133:280–2.e1.e1–2.24369804
  107. Chen H, Common JE, Haines RL, Balakrishnan A, Brown SJ, Goh CS, et al. Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations. Br J Dermatol 2011;165:106–14.21428977
  108. Skjerven HO, Rehbinder EM, Vettukattil R, LeBlanc M, Granum B, Haugen G, et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet 2020;395:951–61.32087121
  109. Kelleher MM, Cro S, Cornelius V, Lodrup Carlsen KC, Skjerven HO, Rehbinder EM, et al. Skin care interventions in infants for preventing eczema and food allergy. Cochrane Database Syst Rev 2021;2:CD013534.
  110. Van Vogt E, Cro S, Cornelius VR, Williams HC, Askie LM, Phillips R, et al. Individual participant data meta-analysis versus aggregate data meta-analysis: a case study in eczema and food allergy prevention. Clin Exp Allergy 2022;52:628–45.34939249
  111. Zhong Y, Samuel M, van Bever H, Tham EH. Emollients in infancy to prevent atopic dermatitis: a systematic review and meta-analysis. Allergy 2022;77:1685–99.34591995
  112. Kelleher MM, Cro S, Phillips R, Williams HC, Lowe AJ, Boyle RJ. Correspondence to ‘Emollients in infancy to prevent atopic dermatitis: a systematic review and meta-analysis’. Allergy 2022;77:1931–3.35643983
  113. Skjerven HO, Lie A, Vettukattil R, Rehbinder EM, LeBlanc M, Asarnoj A, et al. Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet 2022;399:2398–411.35753340
  114. Danby SG, Al-Enezi T, Sultan A, Chittock J, Kennedy K, Cork MJ. The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis. Br J Dermatol 2011;165:329–34.21564067
  115. Pittet LF, Messina NL, Gardiner K, Freyne B, Abruzzo V, Morrison C, et al. Discordance between diagnosis tools for assessing eczema in infants: a challenge for intervention trials. Dermatitis 2022;33:207–14.35170523
  116. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 2015;350:h2147.25956159
  117. Bradshaw LE, Montgomery AA, Williams HC, Chalmers JR, Haines RH. Two-by-two factorial randomised study within a trial (SWAT) to evaluate strategies for follow-up in a randomised prevention trial. Trials 2020;21:529.32546180
  118. Bradshaw LE, Haines RH, Thomas KS, Chalmers JR, Irvine AD, Williams HC, Brown SJ. Clinical examination for hyperlinear palms to determine filaggrin genotype: a diagnostic test accuracy study. Clin Exp Allergy 2021;51:1421–8.34608691
  119. Danby SG, Andrew PV, Taylor RN, Kay LJ, Chittock J, Pinnock A, et al. Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis. Clin Exp Dermatol 2022;47:1154–64. 10.1111/ced.1514135167133
  120. Chaoimh CN, Lad D, Nico C, Puppels GJ, Wong XFCC, Common JE, et al. Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants – The STOP-AD randomised controlled trial. Allergy 2023;78:984–94.35997592
  121. Fleming S, Bodner C, Devereux G, Russell G, Campbell D, Godden D, Seaton A. An application of the United Kingdom Working Party diagnostic criteria for atopic dermatitis in Scottish infants. J Invest Dermatol 2001;117:1526–30.11886518
  122. Treweek S, Banister K, Bower P, Cotton S, Devane D, Gardner HR, et al. Developing the INCLUDE Ethnicity Framework – a tool to help trialists design trials that better reflect the communities they serve. Trials 2021;22:337.33971916
  123. van Zuuren EJ, Fedorowicz Z, Arents BWM. Emollients and moisturizers for eczema: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol 2017;177:1256–71.28432721
  124. Ridd MJ, Santer M, MacNeill SJ, Sanderson E, Wells S, Webb D, et al. Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial. Lancet Child Adolesc Health 2022;6:522–32.35617974
  125. Eichner B, Michaels LAC, Branca K, Ramsey K, Mitchell J, Morris CD, et al. A community-based assessment of skin care, allergies, and eczema (CASCADE): an atopic dermatitis primary prevention study using emollients-protocol for a randomized controlled trial. Trials 2020;21:243.32131885
  126. Jabbar-Lopez ZK, Ezzamouri B, Briley A, Greenblatt D, Gurung N, Chalmers JR, et al. Randomized controlled pilot trial with ion-exchange water softeners to prevent eczema (SOFTER trial). Clin Exp Allergy 2022;52:405–15.34854157
  127. Brown SJ. Atopic eczema: how genetic studies can contribute to the understanding of this complex trait. J Invest Dermatol 2022;142:1015–9.35007558
  128. Garcia-Larsen V, Ierodiakonou D, Jarrold K, Cunha S, Chivinge J, Robinson Z, et al. Diet during pregnancy and infancy and risk of allergic or autoimmune disease: a systematic review and meta-analysis. PLOS Med 2018;15:e1002507.29489823
  129. Kelleher MM, Cro S, Van Vogt E, Cornelius V, Lodrup Carlsen KC, Ove Skjerven H, et al. Skincare interventions in infants for preventing eczema and food allergy: a cochrane systematic review and individual participant data meta-analysis. Clin Exp Allergy 2021;51:402–18.33550675
← ConclusionsAdditional information →

Attribution. Lucy E Bradshaw; Laura A Wyatt; Sara J Brown; Rachel H Haines; Alan A Montgomery; Michael R Perkin et al. (2024). Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT. National Institute for Health and Care Research. Copyright © 2024 Bradshaw et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK605005. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support